Last reviewed · How we verify

Demethylchlortetracycline (DEMECLOCYCLINE)

Pfizer · FDA-approved approved Small molecule Quality 51/100

Demethylchlortetracycline (generic name: DEMECLOCYCLINE) is a Tetracycline-class Antimicrobial Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1960) for Actinomycotic infection, Acute bacterial sinusitis, Acute gonococcal cervicitis.

Demethylchlortetracycline (DEMECLOCYCLINE) is a tetracycline-class antimicrobial drug originally developed by Lederle and currently owned by the same company. It targets the estrogen receptor beta and has been FDA-approved since 1960 for various bacterial infections, including actinomycotic infections, acute bacterial sinusitis, and anthrax. The drug is a small molecule with a half-life of 12 hours and bioavailability of 66%. It is off-patent and has multiple generic manufacturers. Key safety considerations include its potential to interact with other medications and affect liver function.

At a glance

Generic nameDEMECLOCYCLINE
SponsorPfizer
Drug classTetracycline-class Antimicrobial
TargetEstrogen receptor beta
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved
First approval1960

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Demethylchlortetracycline

What is Demethylchlortetracycline?

Demethylchlortetracycline (DEMECLOCYCLINE) is a Tetracycline-class Antimicrobial drug developed by Pfizer, indicated for Actinomycotic infection, Acute bacterial sinusitis, Acute gonococcal cervicitis.

What is Demethylchlortetracycline used for?

Demethylchlortetracycline is indicated for Actinomycotic infection, Acute bacterial sinusitis, Acute gonococcal cervicitis, Acute gonococcal endometritis, Acute gonococcal urethritis.

Who makes Demethylchlortetracycline?

Demethylchlortetracycline is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Demethylchlortetracycline?

DEMECLOCYCLINE is the generic (nonproprietary) name of Demethylchlortetracycline.

What drug class is Demethylchlortetracycline in?

Demethylchlortetracycline belongs to the Tetracycline-class Antimicrobial class. See all Tetracycline-class Antimicrobial drugs at /class/tetracycline-class-antimicrobial.

When was Demethylchlortetracycline approved?

Demethylchlortetracycline was first approved on 1960.

What development phase is Demethylchlortetracycline in?

Demethylchlortetracycline is FDA-approved (marketed).

What are the side effects of Demethylchlortetracycline?

Common side effects of Demethylchlortetracycline include Hepatitis, Liver failure, Pancreatitis, Hepatic toxicity, Acute renal failure, Rise in BUN.

What does Demethylchlortetracycline target?

Demethylchlortetracycline targets Estrogen receptor beta and is a Tetracycline-class Antimicrobial.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing